Hair Loss Treatment: What Works, and Why the Warnings Differ by Country

What causes it

The main drivers in male pattern loss are genetic predisposition and androgens. In affected areas, 5-alpha-reductase activity runs high, producing more dihydrotestosterone.

About half of all men are affected after the age of 50, with onset usually in the thirties or forties, sometimes around puberty. Worldwide the condition reaches roughly 50 percent of men, and an estimated 50 million in the United States.

Physically it is benign. It also tracks with lower self-esteem, body dissatisfaction, social anxiety and reduced quality of life. Saying a condition is not dangerous is not the same as saying it does not matter.

What the evidence supports

The clearest single document on this comes from Japan. The Japanese Dermatological Association grades each treatment from A to D and publishes the table. Neither the United States nor Korea has an equivalent public grade table.

Treatment	Male pattern	Female pattern
Oral finasteride	A	D
Oral dutasteride	A	D
Topical minoxidil	A	A
Autologous hair transplant	B	C1
LED and low-level laser	B	B
Topical adenosine	B	C1
Topical carpronium chloride	C1	C1
Topical t-flavanone	C1	C1
Artificial hair implant	D	D

Table: recommendation grades from the Japanese Dermatological Association guideline on male and female pattern hair loss. A means strongly recommended, D means not recommended.

One row deserves to be pulled out. For female pattern loss, finasteride and dutasteride are graded D. The same drugs that rate A in men fall to not recommended in women.

The guideline also addresses oral minoxidil, which is not approved in Japan, and states that it should not be used, citing risk. On topical minoxidil it notes that a 5 percent formulation is marketed while 15 percent products and overseas products have unconfirmed safety and are outside its recommendations.

In the United States, topical minoxidil and oral finasteride are the FDA-approved treatments, and finasteride is the only oral drug with FDA approval for the condition. Low-dose oral minoxidil is used off-label.

Judging whether any of it is working takes patience. The British Association of Dermatologists advises that topical minoxidil needs at least six months, and sometimes twelve, before its effect can be assessed.

What is known about the risks

This section is the one that tends to get thinned out, so here it is at full length.

The UK Medicines and Healthcare products Regulatory Agency completed a finasteride safety review in 2024 and introduced strengthened warnings along with a patient alert card. In May 2026 it issued a further safety update, reflecting a European regulatory review and advice from its human medicines committee. New wording was added to the product information for 1mg finasteride, clarifying that sexual dysfunction may contribute to mood disorders and that sexual dysfunction has been reported without accompanying mood changes.

The same document records 19 reports of suicide with a fatal outcome in the agency's Yellow Card data for finasteride. It also states that a reported reaction does not mean the drug caused it. Prescribers are asked to check for a history of depression or suicidal ideation before prescribing, and to monitor for psychiatric and sexual side effects after treatment begins.

The Japanese guideline puts a figure on the sexual side effects, noting that around 1 percent of men taking finasteride report reduced libido or erectile dysfunction, and that PSA readings can come back low after six months.

If mood changes or sexual dysfunction appear during treatment, raise it with a clinician. If you already have a history of depression or suicidal thoughts, that belongs in the conversation before the first prescription rather than after. And if you are struggling with any of this now, it is worth talking to someone rather than working it out alone.

How four countries handle it

Country	Regulatory framing	Route to first-line treatment	Public grade table	Level of evidence
United States	FDA-approved drugs	OTC minoxidil, telehealth prescription	Society guidelines	Medical evidence
United Kingdom	Classed as cosmetic, excluded from NHS	Pharmacy purchase, private prescription	BAD patient information	Medical evidence
Japan	Society guideline led	Clinic prescription, topical minoxidil sold retail	A-to-D society grades	Medical evidence stated
South Korea	Androgenetic loss not covered, alopecia areata covered	Dermatology prescription	None	Society position exists

Table: access to hair loss treatment compared by country. Routes to prescription and insurance coverage differ more than the treatments themselves.

United States: skipping the waiting room

The distinctive feature here is the route. Topical minoxidil sits on a shelf. Oral finasteride is FDA-approved and increasingly reached through telehealth.

In January 2026 the journal JMIR published an analysis of real-world data on adult men prescribed compounded topical finasteride through a national telehealth platform. The author list included researchers employed by that company alongside dermatology researchers at Stanford and Brigham. A study with the vendor among its authors is worth reading with that in mind.

Low-dose oral minoxidil has also entered practice off-label and is now widely prescribed. A multicentre safety study of 1,404 patients appeared in the Journal of the American Academy of Dermatology.

Convenience and oversight do not move together. A drug that British regulators want preceded by a question about depression and suicidal thoughts can, by another route, arrive without a consulting room. Neither system is obviously wrong. They simply placed the safeguard at different points.

What sets those points is the legal category the product is filed under, and sunscreen is the cleanest illustration: the United States regulates it as a drug and the EU as a cosmetic, and the marks on the bottle change with the category.

United Kingdom: the treatment exists, the state will not buy it

The British Association of Dermatologists states that male pattern hair loss is considered a cosmetic condition and is not usually treated on the NHS. Topical minoxidil is not available on NHS prescription and has to be bought directly from a pharmacy. Transplant surgery is not offered on the NHS either, so it happens privately.

The same patient information covers what using it involves. At least six months, sometimes twelve, before the effect can be judged. Dryness, redness, flaking and itching are possible, and it should not be applied to broken skin.

The UK is also where the regulatory tightening happened, which makes an odd pair. The state declines to fund the treatment and simultaneously does the most detailed work on its risks.

Deciding whether a condition is cosmetic is how a system decides who pays. In acne the same line runs through the price of the drug rather than the diagnosis: the 2024 US guideline kept two acne drugs at a weaker recommendation because of cost, not weaker evidence.

Japan: the table nobody else publishes

The A-to-D table above is most of what needs saying.

That a professional society graded ten treatments and published the result is itself an asset. Anyone can check what has evidence behind it and what does not. Artificial hair implants sit at D for both sexes. Low-level laser reaches B. Several topical compounds stall at C1.

Societies do not always converge, though. On eczema, five national guidelines wrote five different sentences about the same disease: what they actually disagree on, from maintenance treatment to how much emollient a week.

For someone searching online at midnight, having that on one page is not a small difference.

South Korea: black beans, and the bill

Korean readers grow up hearing that black beans help with hair loss, and there is a reason the belief took hold. Black beans contain isoflavonoids that weakly inhibit DHT, so the story has a plausible mechanism attached.

Professional bodies have addressed it directly. The Korean Hair Research Society states that no scientifically established effect of black beans or other so-called black foods on hair loss treatment, prevention or greying has been demonstrated. The Korean Dermatological Association of physicians adds that such foods reach only as far as general scalp and hair health, do not halt progression or reverse existing loss, and that the only methods with verified treatment effect are oral and topical drugs and hair transplantation. The same ceiling applies to the products and services sold as scalp care: what the evidence behind head spas, scalp massage and functional shampoos actually reaches.

On coverage, national health insurance applies in a limited way to pathological hair loss such as alopecia areata, where the immune system attacks the follicles. Androgenetic loss, meaning the male and female patterns driven by ageing and genetics, is not covered, and patients pay the full cost.

When to see a doctor

Sharply bordered round patches of loss, or symptoms in the eyebrows or beard, point toward autoimmune alopecia areata rather than pattern loss.

Hair loss driven by an underlying condition such as thyroid disease or iron deficiency needs that condition investigated and treated.

If you are already on treatment, two things. Topical minoxidil needs at least six months before its effect can be judged, so talk to someone before stopping early. And any mood change or sexual dysfunction while taking finasteride belongs in front of a clinician.

Frequently asked questions

Frequently asked

Does finasteride cause depression?

UK regulators strengthened the warnings in May 2026, clarifying that sexual dysfunction may contribute to mood disorders and has also been reported without mood changes. Their Yellow Card data contains 19 reports of suicide with a fatal outcome, and the same document notes that a report does not establish that the drug caused it. Prescribers are asked to check for a history of depression or suicidal ideation beforehand.

How long before minoxidil works?

At least six months, and sometimes twelve, according to British Association of Dermatologists guidance. Dryness, redness, flaking and itching can occur, and it should not go on broken skin.

Can women use finasteride for hair loss?

The Japanese guideline grades finasteride and dutasteride D, not recommended, for female pattern loss, while topical minoxidil rates A for both sexes. Female hair loss needs a clinical assessment rather than a decision made from an article.

Is oral minoxidil safe?

It is used off-label in the United States, with a multicentre safety study of 1,404 patients published in JAAD. Japan has not approved it, and its dermatology society states it should not be used, citing risk. Two regulatory systems reading the same drug differently is a reason to have the conversation with a clinician rather than to pick a side.